Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
9
×
fda
9
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
9
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
clinical trials
nonalcoholic steatohepatitis
cancer immunotherapy
deals
europe blog main
europe top stories
gene therapy
glaxosmithkline
loxo oncology
merck
startups
What
cancer
9
×
roundup
bio
drug
ahead
amid
annual
bombast
cash
caught
clinical
coronavirus
days
debate
develop
discussion
efforts
fda
medicine
meeting
meso’s
miss
new
oncology
pandemic
pfizer’s
presidential
promise
response
society
tuesday’s
vaccine
viewers
abbvie’s
allogene
ambien
american
appetite
approved
asco
Language
unset
Current search:
fda
×
" national top stories "
×
" detroit top stories "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
4 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More